524414 NORRIS

Norris Medicines Share Price

 

 

Start SIP in NORRIS

Start SIP
Norris Medicines live price: ₹13.25. It opened at ₹14 vs previous close ₹14; intraday high/low: ₹14/₹13. The 50 & 200 DMA stand at ₹14.26/₹15.74.

Norris Medicines Performance

  • Low
  • ₹13
  • High
  • ₹14
  • 52 Week Low
  • ₹13
  • 52 Week High
  • ₹22
  • Open Price₹14
  • Previous Close₹14
  • Volume229
  • 50 DMA₹14.26
  • 100 DMA₹14.88
  • 200 DMA₹15.74

Investment Returns

  • Over 1 Month -1.12%
  • Over 3 Month -25.89%
  • Over 6 Month -23.98%
  • Over 1 Year -27.79%

Smart Investing Starts Here Start SIP with Norris Medicines for Steady Growth!

Invest Now

Norris Medicines Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -23.7
  • PEG Ratio
  • -0.7
  • Market Cap Cr
  • 13
  • P/B Ratio
  • -0.9
  • Average True Range
  • 1.25
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.08
  • RSI
  • 45.29
  • MFI
  • 76.88

Norris Medicines Financials

Norris Medicines Technicals

EMA & SMA

Current Price
₹13.25
-0.5 (-3.64%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹13.91
  • 50 Day
  • ₹14.26
  • 100 Day
  • ₹14.88
  • 200 Day
  • ₹15.74

Resistance and Support

13.58 Pivot Speed
  • R3 14.92
  • R2 14.58
  • R1 13.92
  • S1 12.92
  • S2 12.58
  • S3 11.92

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Norris Medicines has an operating revenue of Rs. 9.44 Cr. on a trailing 12-month basis. An annual revenue growth of 4% is not great, Pre-tax margin of -20% needs improvement, NULL From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 34 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 62 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Norris Medicines Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-14 Quarterly Results
2025-11-14 Quarterly Results
2025-08-14 Quarterly Results
2025-05-28 Audited Results
2025-02-13 Quarterly Results & Others Inter-alia, to consider 1. Requests from Mr. Nimish Bhishma Thakore, for reclassification from Promoter / Promoter Group into Public Category. 2. Other business matters.

Norris Medicines F&O

Norris Medicines Shareholding Pattern

34%
0.01%
0.06%
20.79%
45.14%

Norris Medicines FAQs

Norris Medicines share price is ₹13 As on 17 March, 2026 | 20:27

The Market Cap of Norris Medicines is ₹13.3 Cr As on 17 March, 2026 | 20:27

The P/E ratio of Norris Medicines is -23.7 As on 17 March, 2026 | 20:27

The PB ratio of Norris Medicines is -0.9 As on 17 March, 2026 | 20:27

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23